According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Separately, JPMorgan Chase & Co. set a $26.00 target price on shares of Enanta Pharmaceuticals and gave the company a buy rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $27.24.
Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 0.97% on Tuesday, reaching $25.99. 6,150 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $24.53 and a 200-day moving average price of $24.87. Enanta Pharmaceuticals has a 1-year low of $16.75 and a 1-year high of $41.77. The company has a market capitalization of $494.72 million, a P/E ratio of 17.19 and a beta of 0.52.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. Enanta Pharmaceuticals had a net margin of 32.59% and a return on equity of 11.31%. The business earned $14 million during the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter in the prior year, the business posted $0.13 EPS. The company’s revenue for the quarter was up 20.7% on a year-over-year basis. Equities research analysts expect that Enanta Pharmaceuticals will post $1.02 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of ENTA. Public Employees Retirement System of Ohio increased its position in shares of Enanta Pharmaceuticals by 4.0% in the second quarter. Public Employees Retirement System of Ohio now owns 19,209 shares of the company’s stock worth $424,000 after buying an additional 747 shares during the last quarter. Fiera Capital Corp purchased a new position in shares of Enanta Pharmaceuticals during the second quarter worth approximately $12,480,000. AQR Capital Management LLC increased its position in shares of Enanta Pharmaceuticals by 6.5% in the second quarter. AQR Capital Management LLC now owns 46,258 shares of the company’s stock worth $1,020,000 after buying an additional 2,822 shares during the last quarter. Guggenheim Capital LLC increased its position in shares of Enanta Pharmaceuticals by 16.2% in the second quarter. Guggenheim Capital LLC now owns 36,718 shares of the company’s stock worth $809,000 after buying an additional 5,118 shares during the last quarter. Finally, Senzar Asset Management LLC increased its position in shares of Enanta Pharmaceuticals by 42.2% in the second quarter. Senzar Asset Management LLC now owns 482,000 shares of the company’s stock worth $10,628,000 after buying an additional 143,149 shares during the last quarter. Hedge funds and other institutional investors own 70.82% of the company’s stock.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.